<DOC>
	<DOCNO>NCT01960686</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety multiple formulation RSV-F protein nanoparticle vaccine , aluminum , healthy woman child-bearing age .</brief_summary>
	<brief_title>RSV F Dose-Ranging Study Women</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects must meet follow criterion eligible participate : 1 . Healthy adult female , ≥ 18 ≤ 35 year age . `` Healthy '' shall define absence illness , acute chronic , require ongoing systemic therapy control symptoms prevention disability . Subjects stable ( change ≥ 3 month ) therapy finding ( e.g. , hypertension hyperlipidemia ) associate symptoms disability eligible , users hormonal contraceptive . Subjects receive intermittent prophylaxis risk associate asymptomatic finding ( e.g. , antibiotic prophylaxis prior dental procedure subject mitral valve prolapse ) eligible . Ongoing therapy define continuous , intermittent , frequent every 3 month ( e.g. , use inhale bronchodilator exerciseinduced bronchospasm every 3 month ) . Immunosuppressives subject exclusion criterion # 5 . Persons treat illness condition would become acutely symptomatic disable absence treatment eligible . 2 . Willing able give inform consent prior study enrollment . 3 . Able comply study requirement . 4 . Women surgically sterile must negative urine pregnancy test prior vaccination ; advise Informed Consent process avoid become pregnant duration study , must assert employ effective form birth control duration study . Acceptable form birth control : credible history continuous abstinence heterosexual activity , hormonal contraceptive ( oral , injectable , implant , patch , ring ) , doublebarrier contraceptive ( condom diaphragm , spermicide ) , IUD . Subjects exclude fulfill follow criterion : 1 . Participation research involve investigational product ( drug / biologic / device ) within 45 day plan date first vaccination . 2 . History serious reaction prior vaccination . 3 . Received vaccine 4 week precede study vaccination ; RSV vaccine time . 4 . Any known suspected immunosuppressive condition , acquire congenital , determined history and/or physical examination . 5 . Chronic administration ( define 14 continuous day ) immunosuppressant immunemodifying drug within 6 month prior administration study vaccine . An immunosuppressant dose glucocorticoid define systemic dose ≥10mg prednisone per day equivalent . The use topical , inhaled , nasal glucocorticoid permit . 6 . Administration immunoglobulins and/or blood product within 3 month precede administration study vaccine study . 7 . Donated blood within 3 week plan date first vaccination . 8 . Acute disease time enrollment ( define presence moderate severe illness without fever , oral temperature &gt; 38.0°C planned day vaccine administration ) . 9 . Known disturbance coagulation . 10 . Women pregnant breastfeeding , plan become pregnant study . 11 . Suspicion recent history ( within one year plan vaccination ) alcohol substance abuse . 12 . Any condition opinion Investigator would pose health risk subject enrol could interfere evaluation vaccine interpretation study result ( include neurologic psychiatric condition deem likely impair quality safety reporting ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>